Recombinant Herpesvirus Glycoprotein G Improves the Protective Immune Response to Helicobacter pylori Vaccination in a Mouse Model of Disease

Louise Baker1, Andre M. L. Chitas2, Carol A. Hartley3, Mauricio J. C. Coppo2, Paola K. Vaz2, Andrew Stent1, James R. Gilkerson3, Joanne M. Devlin2*, Alison L. Every1*,

1 Centre for Animal Biotechnology, Faculty of Veterinary Science, The University of Melbourne, Parkville, VIC, Australia, 2 Asia-Pacific Centre for Animal Health, Faculty of Veterinary Science, The University of Melbourne, Parkville, VIC, Australia, 3 Centre for Equine Infectious Disease, Faculty of Veterinary Science, The University of Melbourne, Parkville, VIC, Australia

Abstract

Alphaherpesviruses, which have co-evolved with their hosts for more than 200 million years, evade and subvert host immune responses, in part, by expression of immuno-modulatory molecules. Alphaherpesviruses express a single, broadly conserved chemokine decoy receptor, glycoprotein G (gG), which can bind multiple chemokine classes from multiple species, including human and mouse. Previously, we demonstrated that infection of chickens with an infectious laryngotracheitis virus (ILTV) mutant deficient in gG resulted in altered host immune responses compared to infection with wild-type virus. The ability of gG to disrupt the chemokine network has the potential to be used therapeutically. Here we investigated whether gG from ILTV or equine herpesvirus 1 (EHV-1) could modulate the protective immune response induced by the Helicobacter pylori vaccine antigen, catalase (KatA). Subcutaneous immunisation of mice with KatA together with EHV-1 gG, but not ILTV gG, induced significantly higher anti-KatA IgG than KatA alone. Importantly, subcutaneous or intranasal immunisation with KatA and EHV-1 gG both resulted in significantly lower colonization levels of H. pylori colonization following challenge, compared to mice vaccinated with KatA alone. Indeed, the lowest colonization levels were observed in mice vaccinated with KatA and EHV-1 gG, subcutaneously. In contrast, formulations containing ILTV gG did not affect H. pylori colonisation levels. The difference in efficacy between EHV-1 gG and ILTV gG may reflect the different spectrum of chemokines bound by the two proteins. Together, these data indicate that the immuno-modulatory properties of viral gGs could be harnessed for improving immune responses to vaccine antigens. Future studies should focus on the mechanism of action and whether gG may have other therapeutic applications.

Introduction

Alphaherpesviruses are a family of large double stranded DNA viruses that cause disease in humans and animals. Herpesviruses have been co-evolving with their hosts for more than 200 million years and utilize many strategies to subvert host immune responses, including decoy receptors that bind chemokines and modulate host responses to infection [1–3]. Alphaherpesviruses have only one broadly conserved chemokine decoy receptor, glycoprotein G (gG). Glycoprotein G from most alphaherpesviruses function as broad-spectrum viral chemokine binding proteins (vCKBP) s in vitro [4–7]. Chemokines are small molecular mass cytokines that recruit and activate cells of the immune system. The chemokine network is a major target for immune-modulating drugs [8–12]. Glycoprotein G from diverse alphaherpesviruses bind a broad range of chemokine classes from several different species, including human and mouse species [4,5,7]. The chemokine-binding specificity of the gGs from at least 7 different herpesviruses have been studied and bind to a broad range of chemokines, including human and mouse CC and CXC chemokines. All gG homologues tested (except gG from equine herpesvirus 4) bind human CXCL11, 12, 15 and 14, and show variable binding to many other human CCL, CXCL, and CL chemokines [4–7,13,14].

Our previous studies of gG have made extensive use of avian infectious laryngotracheitis virus (ILTV) infection experiments in the natural host (chicken). This virus causes acute respiratory disease in poultry worldwide. Our in vivo studies have shown that gG modulates the inflammatory response and consequent adaptive immune response to alphaherpesvirus infection. In infection studies using wild-type and gG-deficient constructs of ILTV, the presence of gG results in increased recruitment of B cells and...
reduced recruitment of T cells and heterophils (avian neutrophil equivalent) to the site of infection [7]. Consistent with this finding, infection with gG-deficient ILTV results in significantly reduced serum and tracheal antibody titres to ILTV, yet can induce protective immunity from challenge with virulent ILTV [7,13–17]. Animal models of human diseases have demonstrated therapeutic applications of other vCKBPs (from poxviruses) to alter host immune responses and reduce inflammation [18,19], however the therapeutic use of gG has not been explored. As gG has no amino acid similarity with other vCKBPs, or with host chemokine receptors [5], this glycoprotein represents a novel protein structure that has the potential to be used therapeutically to influence the chemokine network. This study aims to explore whether recombinant gG from either a mammalian herpesvirus (equine herpesvirus 1, EHV-1) or avian herpesvirus (ILTV) can modulate the immune response to heterologous antigen using vaccination against the Gram negative human stomach pathogen, Helicobacter pylori, as a model.

Helicobacter pylori is one example of a bacterial infection for which many have attempted to develop a vaccine, with minimal success thus far [20]. Several human clinical trials have tested urease as the antigen, delivered in combination with the adjuvant, heat-labile toxin from Escherichia coli [21–23]. In one study, a significant reduction in bacterial load was noted, which was accompanied by induction of anti-H. pylori serum IgA and anti-H. pylori peripheral blood mononuclear antibody-secreting cells (ASCs) [21], although more than half the participants developed diarrhoea. To circumvent toxicity issues associated with LT, urease expressed more than half the participants developed diarrhoea. To blood mononuclear antibody-secreting cells (ASCs) [21], although the therapeutic use of gG has not been explored. As gG has no amino acid similarity with other vCKBPs, or with host chemokine receptors [5], this glycoprotein represents a novel protein structure that has the potential to be used therapeutically to influence the chemokine network. This study aims to explore whether recombinant gG from either a mammalian herpesvirus (equine herpesvirus 1, EHV-1) or avian herpesvirus (ILTV) can modulate the immune response to heterologous antigen using vaccination against the Gram negative human stomach pathogen, Helicobacter pylori, as a model.

Helicobacter pylori is one example of a bacterial infection for which many have attempted to develop a vaccine, with minimal success thus far [20]. Several human clinical trials have tested urease as the antigen, delivered in combination with the adjuvant, heat-labile toxin from Escherichia coli [21–23]. In one study, a significant reduction in bacterial load was noted, which was accompanied by induction of anti-H. pylori serum IgA and anti-H. pylori peripheral blood mononuclear antibody-secreting cells (ASCs) [21], although more than half the participants developed diarrhoea. To circumvent toxicity issues associated with LT, urease expressed more than half the participants developed diarrhoea. To blood mononuclear antibody-secreting cells (ASCs) [21], although the therapeutic use of gG has not been explored. As gG has no amino acid similarity with other vCKBPs, or with host chemokine receptors [5], this glycoprotein represents a novel protein structure that has the potential to be used therapeutically to influence the chemokine network. This study aims to explore whether recombinant gG from either a mammalian herpesvirus (equine herpesvirus 1, EHV-1) or avian herpesvirus (ILTV) can modulate the immune response to heterologous antigen using vaccination against the Gram negative human stomach pathogen, Helicobacter pylori, as a model.

Chemokine-binding Enzyme-Linked Immunosorbent Assay (ELISA) Using EHV-1 gG To assess the chemokine binding activity of recombinant EHV-1 gG, flat bottom microtitre plate wells (Nunc Polysorb, Penfield, NY, USA) were coated with dilutions of recombinant chemokine, in coating buffer (16 mM Na₂CO₃, 34 mM NaHCO₃, pH 9.6), beginning at a concentration of 6 μg/mL. Human IL-8 was used as a positive control for binding. Plates were covered and incubated overnight at 4°C prior to washing with PBS containing 0.05% v/v Tween 20 (PBS-T), and blocking for 2 hrs at 37°C with 10 mg/mL bovine serum albumin (BSA) in PBS (PBS-BSA) containing 5% v/v normal sheep serum. Plates were washed with PBS-T and incubated for 2 hrs at room temperature (RT) with EHV-1 gG (3 μg/mL) in BSA diluent (5 mg/ml BSA, PBS-T, 2.5% v/v normal sheep serum). Following washing with PBS-T, plates were incubated with a 1/100 dilution of hyperimmune rat serum to the variable region of EHV-1 gG [28] for 2 hrs at RT. Plates were washed and incubated for 1 hr with HRP-conjugated goat anti-rat IgG secondary antibody at RT. The plates were washed and developed using tetramethylbenzidine substrate (0.1 mg/mL, Sigma-Aldrich, St Louis, MO, USA) in developing buffer (0.1 M Na₂HPO₄, 0.05 M citric acid, pH 5.0, 0.006% v/v H₂O₂), and the reaction stopped by adding 1 M HCl. Absorbance readings with backgrounds subtracted (derived from wells containing no gG) were determined at a wavelength of 450 nm (Labsystems Multiskan MS).

Mice BALB/c mice were purchased from The Walter & Eliza Hall Institute and maintained in the Animal House Facility at Veterinary Science, University of Melbourne. All procedures were subject to approval from the University of Melbourne Animal Ethics Committee in accordance with the Australian Code of Practice for the care and use of animals for scientific purposes.
**H. Pylori Culture**

_H. pylori_ strain SS1 [29] was grown on horse blood agar plates and sub-cultured into brain heart infusion broth as described [30].

**Helicobacter Pylori Vaccination/Challenge**

Recombinant, his-tagged _Helicobacter pylori_ catalase (KatA) was synthesised and purified over Ni-NTA columns as described [31] and used in vaccination/challenge studies. Mice (n = 8) were vaccinated twice, three weeks apart as outlined in Table 1. Two additional groups were left unvaccinated. Four weeks after the second vaccination mice were challenged with _H. pylori_ (10⁷ CFU) via oro-gastric gavage. Mice were euthanised four weeks after infection for assessment of bacterial burden by colony-forming unit assay as described [30].

**Determination of Serum IgG Titre**

Sera were collected by cardiac puncture and anti-Helicobacter pylori catalase antibody levels determined by standard direct ELISA as described [30]. Briefly, Maxisorp immunoplates (Nunc, Roskilde, Denmark) were coated overnight with 0.25 μg recombinant KatA in bicarbonate buffer pH 9.6. After blocking with PBS-BSA serial dilutions of sera were added to duplicate wells. After washing, HRP-conjugated goat anti-mouse IgG Fc (Pierce, Rockford, IL; diluted 1:5000 in PBS-BSA) was added. Colour was developed by addition of 100 μL 3,3′,5,5′-tetramethylbenzidine (Invitrogen, Carlsbad, CA), and the reaction was stopped by adding 2 M H₂SO₄. Absorbance was read at 450 nm and mid-point titres calculated.

**Assessment of Gastritis**

Gastritis was assessed histologically as described [32]. Briefly, half stomachs were fixed in 10% neutral-buffered formalin, processed, and embedded in paraffin wax. Sections (4 μm) were stained with haematoxylin and eosin and histopathology was scored by a blinded assessor according to the following scheme: Cellular infiltrate 0–6: 0, none; 1 mild, multifocal; 2 mild, widespread or moderate multifocal; 3, mild widespread and moderate multifocal or severe multifocal; 4, moderate widespread; 5, moderate widespread and severe multifocal; and 6, severe widespread. Mucus metaplasia and functional atrophy 0–3: 0, absent; 1, mild; 2, moderate; and 3, severe.

**Statistical Analysis**

One-way analysis of variance (ANOVA) with Dunnett’s Multiple Comparison Test was used to assess differences in gastritis development. Kruskal-Wallis one-way ANOVA with Dunn’s multiple comparison test was used to analyse ELISA and CFU data. All analysis was performed using GraphPad Prism software (Version 5, San Diego, CA, USA). A p-value of less than 0.05 was considered to indicate statistical significance.

**Results**

**Synthesis and Purification of gG**

Recombinant, purified EHV-1gG was separated by SDS-PAGE and stained with Coomassie Brilliant Blue (Figure 1A). Western blots were probed with EHV-1 gG specific polyclonal antiserum, and detected an approximately 48 kDa protein consistent with the band size observed in Coomassie Brilliant Blue stains (Figure 1B). This is consistent with the expected size of this glycoprotein, consisting of a 39.3 kDa amino acid backbone and 6 potential N-linked glycosylation sites. Results from Coomassie Brilliant Blue staining and Western blotting of recombinant, purified ILTV gG following SDS-PAGE were consistent with those described in previous studies [7] (not shown).

**EHV-1 gG Binds CCL5, CCL11 and the Th2 Cytokine, IL-4**

Chemokine-binding ELISAs utilised in this study yielded results consistent with previous studies [5,13,33] and showed that recombinant EHV-1 gG binds to mXCL1 and eIL-8 with the highest binding levels to hIL-8 and no binding to hCX3CL1 and eCCL2 (not shown). In addition, recombinant EHV-1 gG bound CCL5 and CCL11 (human, murine, equine) with some variation.

![Figure 1. Recombinant EHV-1 gG purified from a baculovirus expression system.](https://example.com/figure1.png)
in binding observed between chemokines from the different species of origin (Figure 2). EHV-1 gG bound only to mouse CCL11 and poorly, if at all, to equine or human CCL11 (Figure 2). While EHV-1 gG bound the Th2 cytokine, IL-4 (murine), it failed to bind human and equine IL-4 or any species of the T-cell proliferative and memory maintenance cytokine, IL-15.

EHV-1 gG, but not ILTV gG, Boosts Immunity to *H. Pylori* Catalase

EHV-1 gG binds a broad range of murine and human chemokines (Bryant et al, 2003) suggesting that it has the capacity to modulate immune responses in multiple species. ILTV also has the capacity to bind murine and human chemokines, albeit a narrower range (Devlin et al, 2010). Consequently, we chose to test the immuno-modulatory potentials of EHV-1 and ILTV gG in an established murine vaccine/challenge model for *Helicobacter pylori*. We selected KatA as the vaccine antigen, which we and others have previously shown to induce protective immunity in mice when delivered with an appropriate adjuvant [31,34,35]. We co-delivered gG with catalase on two occasions, three weeks apart – a regimen that has proven effective in our laboratory [30,31]. Serum IgG levels measured one week after the second vaccination indicated that, as expected, a strong antibody response was elicited in mice vaccinated with KatA and CT (Figure 3), which was significantly higher than in mice vaccinated with KatA alone (**p<0.01; Kruskal-Wallis with Dunn’s multiple comparison). Serum IgG was significantly boosted when compared to mice vaccinated with KatA alone (*p<0.05; Kruskal-Wallis with Dunn’s multiple comparison). These data indicate that EHV-1 gG, but not ILTV gG, can boost immune responses to vaccine antigens, when delivered via the s.c. route.

Mice Immunised with *H. Pylori* Catalase and EHV-1 gG, but not ILTV gG, have Reduced Bacterial Burden Following Challenge

Mice vaccinated with KatA alone did not have significantly reduced bacterial burdens after challenge when compared to unvaccinated mice, via either the i.n. or s.c. route (Figure 4). As anticipated mice that were vaccinated with KatA adjuvanted with CT i.n. or with formalin-fixed whole bacteria s.c. had significantly reduced bacterial burdens when compared to unvaccinated mice or mice vaccinated with KatA alone (Figure 4). Subcutaneous delivery of KatA + EHV-1 gG resulted in a highly significant reduction in bacterial load observed when compared to unvaccinated mice (***p<0.001). Mice vaccinated with KatA + EHV-1 gG via the i.n. route also showed a significant reduction in bacterial loads following challenge (Figure 4A, *p<0.05). In contrast, bacterial burdens in mice vaccinated with KatA + ILTV gG were not reduced (Figure 4B).

Reduced Bacterial Burdens in Mice Immunised with *H. Pylori* Catalase and EHV-1 gG is not due to Post-immunisation Gastritis

Stomachs were examined histologically to determine whether increased generalised inflammation could account for the reduced bacterial burdens in mice immunised with *H. pylori* catalase and...
EHV-1 gG. All mice infected with H. pylori exhibited mild cellular infiltrate (Table 2). There was significantly more cellular infiltrate (p<0.01), mucus metaplasia (p<0.05) and atrophy (p<0.05) in mice that were vaccinated with H. pylori catalase and chlorella toxin i.n. when compared with mice that were challenged, but unvaccinated. However, mice in the groups that were vaccinated with H. pylori catalase and EHV-1 gG did not show significantly more severe gastritis than mice that were unvaccinated/challenged.

Discussion

This is the first in vivo investigation into the use of alphaherpesvirus gG to alter immune responses to a heterologous antigen. The results showed that EHV-1 gG, but not ILTV gG, enhanced protective immune responses to H. pylori KatA antigen.

In this study, our investigations confirmed that recombinant EHV-1 gG binds a broad range of chemokines, consistent with findings from previous studies [5,7,13]. Moreover, in addition to its broad-spectrum chemokine-binding ability, EHV-1 gG was also found to bind to the murine Th2 cytokine, IL-4. This is the first report of any species of viral glycoprotein G binding to a non-chemokine cytokine. We tested the capacity of EHV-1 gG and ILTV gG to modulate immune responses to a vaccine antigen in a mouse H. pylori vaccine/challenge model, and whether this could substantially impact upon bacterial burdens. These Gram negative bacteria infect the stomachs of approximately half the world’s population, and are the major cause of gastric cancer. Although currently treated with a combination of two antibiotics and a proton pump inhibitor, like many bacterial diseases, the rising prevalence of antibiotic-resistant strains is of increasing concern. A recent multi-centre survey in Europe highlighted increasing prevalence of resistance to clarithromycin as well as the emergence of levofloxacin-resistant strains [36]. These concerning findings emphasise the need to develop novel therapeutics; vaccines represent the most cost-effective way of tackling this disease [37]. As another pathogen that has co-evolved with its human host over millennia [38], H. pylori has developed numerous strategies to evade host immune responses and subsequent clearance [37]. These adaptations are particularly evident when considering vaccination protocols tested in mice usually only result in a one- to two-log fold reduction in bacterial burdens at best, even when antigens are co-delivered with the ‘gold standard’ mucosal adjuvant, chlorella toxin [30,31]. We recently postulated that modulation of the inflammatory response through manipulation of the chemokine and cytokine milieu could represent a novel and improved approach to induce robust immune responses to H. pylori vaccine antigens and may subsequently improve vaccine efficacy [37]. A vCKBP has the potential to fulfil this role.

This study tested whether glycoprotein G derived from EHV-1 or ILTV could be used to modulate immune responses to recombinant H. pylori catalase and whether this would lead to protective immunity against H. pylori challenge. When delivered i.n., a significantly higher titred antibody response was induced in mice that received KatA plus EHV-1 gG than in mice that were immunised with KatA alone. An enhanced protection by way of reduced bacterial burdens was then detected following challenge. Although there was no detectable enhancement in the antibody response to KatA when co-delivered with EHV-1 gG via the i.n. route, a significant reduction in bacterial burden was observed when compared to mice that received KatA alone. Th1 immunity, rather than Th2 immunity is reportedly essential for H. pylori vaccine-mediated protection [39] and so it is inconceivable that an enhanced level of protection was observed in the absence of an increased antibody response. Importantly, non-specific inflammation did not account for the reduction in bacterial burdens observed following immunisation with KatA + EHV-1 gG, which was no worse than the mild gastritis observed in unvaccinated/challenged mice. Gastritis is commonly associated with H. pylori vaccines [40] and was evident here in the KatA + CT i.n. group.

In contrast to EHV-1 gG, ILTV gG did not boost antibody responses to KatA and failed to effect any protection by way of reduced bacterial burdens. The differences between the in vivo effects of EHV-1 and ILTV gG in this model may be related to differences in their chemokine-binding profiles. EHV-1 gG is considered a broad-spectrum chemokine binding protein [5] but has only been tested against a limited range of murine chemokines. In previous studies EHV-1 gG has shown binding to murine chemokines from the CCL subfamily (CCL5, CCL11) and the CXCL subfamily (CXCL1, CXCL2, CXCL9, CXCL13) as well as the murine chemokine XCL1. EHV-1 gG has not shown binding to murine chemokines CXCL10, CXCL12, CXCL2, CXCL3, CXCL20, CXCL21, CXCL27 or CXCL31 [5]. ILTV gG is considered to bind a narrower range of chemokines but has been tested against a greater range of murine chemokines. It has shown binding to murine chemokines in the CCL subfamily (CCL21, CCL24, CCL25, CCL27, CCL28) and the CXCL subfamily.
CXCL11, CXCL12, CXCL13, CXCL14 [7]. ILTV gG has not shown binding to murine chemokines CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9/10, CCL11, CCL12, CCL17, CCL19, CCL20, CXCL1, CXCL2, CXCL4, CXCL5, CXCL9, CXCL15 or CXCL16 [7]. Future studies to more comprehensively investigate the breadth and strength of EHV-1 gG binding to chemokines, similar to those performed for ILTV gG [7] are indicated. Interestingly, previous studies have suggested that ILTV gG may act to skew the host immune response towards a Th2-mediated response [7] but a similar role for EHV-1 gG has not been described [41]. These differences could be related to the different effects of EHV-1 and ILTV gG in this model, which

![Figure 4](image)

**Figure 4. Immunisation with KatA and EHV-1 gG, but not ILTV gG, resulted in reduced *H. pylori* colonisation levels.** BALB/c mice were not vaccinated (unvacc) or vaccinated via the i.n. route recombinant catalase (KatA) alone (10 μg), KatA + CT (10 μg of each) or KatA and either A) EHV-1 gG or B) ILTV gG (10 μg of each). Mice vaccinated subcutaneously received recombinant catalase (KatA) alone (10 μg), formalin-fixed *H. pylori* (FF-Hp) or KatA and either A) EHV-1 gG or B) ILTV gG (10 μg of each), or were not vaccinated (unvacc). Four weeks after the second vaccination, mice were challenged with *H. pylori* (10^7, oro-gastric delivery). Box plots represent the median (horizontal line), interquartile range (box) and the 10th and 90th percentiles (whiskers). *p<0.05, **p<0.005, ***p<0.0005, compared to unvaccinated group; Kruskal-Wallis with Dunn’s Multiple Comparison test. doi:10.1371/journal.pone.0096563.g004

**Table 2. Histopathology scores in mice.**

| Vaccination                  | Cellular infiltrate (interquartile ranges) | Mucus metaplasia (interquartile ranges) | Atrophy (interquartile ranges) |
|-----------------------------|-------------------------------------------|----------------------------------------|--------------------------------|
| Unvaccinated/unchallenged   | 0 (0–1)                                   | 0 (0–0)                                | 0 (0–0)                        |
| Unvaccinated/challenged     | 2 (1–2)                                   | 0 (0–0)                                | 0 (0–0)                        |
| Catalase i.n.               | 0.5 (0–1.75)                              | 0 (0–0)                                | 0 (0–0)                        |
| Catalase + CT i.n.          | 3.5 (2.25–4)**                            | 0 (0–0.75)*                            | 0 (0–1)**                      |
| Catalase + EHV-1 gG i.n.   | 1.5 (1–2)                                 | 0 (0–0)                                | 0 (0–0)                        |
| Catalase s.c.               | 2 (1–2.75)                                | 0 (0–0)                                | 0 (0–0)                        |
| Formalin-fixed *H. pylori* s.c. | 2 (2–2.75)                              | 0 (0–0)                                | 0 (0–0)                        |
| Catalase + EHV-1 gG s.c.   | 2.0 (2–3)                                 | 0 (0–0)                                | 0 (0–0)                        |

*Cellular infiltrate (0–6): 0, none; 1 mild, multifocal; 2 mild, widespread or moderate multifocal; 3, mild widespread and moderate multifocal or severe multifocal; 4, moderate widespread; 5, moderate widespread and severe multifocal; and 6, severe widespread. Mucus metaplasia and functional atrophy (0–3): 0, absent; 1 mild; 2 moderate; and 3 severe. *p<0.05, **p<0.01, c.f. unvaccinated/challenged group; One-way ANOVA with Dunnett’s Multiple Comparison Test doi:10.1371/journal.pone.0096563.t002
requires Th1 immune responses for protection. Clarifying whether EHV-1 gG chemokine-binding with subsequent modulation of T-cell responses is the mechanism responsible for the protective immunity observed is of utmost priority in future studies to reach a full understanding of how gG can enhance immunity. The finding of this study presents a promising avenue for development of novel vaccine adjuvants and warrants further investigation, which should focus on the mechanism of action. Moreover, by increasing our understanding of v-CKBP interaction with chemokines and cytokines, we envisage the potential to develop tailored adjuvants with specific chemokine-binding profiles that can then be utilised for highly specific vaccines. This technology has potential applications not just for development of efficacious *H. pylori* vaccines, but vaccines for other infectious diseases.

**Author Contributions**

Conceived and designed the experiments: LB CAH JRG JMD ALE. Performed the experiments: LB AMLC PKV ALE. Analyzed the data: LB AMLC CAH JRG JMD ALE. Contributed reagents/materials/analysis tools: MJCC PKV AS. Wrote the paper: LB AMLC CAH JMD ALE.

**References**

1. Alcami A, Lira SA (2010) Modulation of chemokine activity by viruses.Curr Opin Immunol 22: 462–467.
2. Alcami A, Saraiva M (2009) Chemokine binding proteins encoded by pathogens. Adv Exp Med Biol 666: 167–179.
3. Webb LM, Alcami A (2005) Virally encoded chemokine binding proteins. Mini Rev Med Chem 5: 833–840.
4. Viejo-Borbolla A, Martínez-Martín N, Nel HJ, Rueda P, Martin R, et al. (2012) Enhancement of chemokine function as an immunomodulatory strategy employed by human herpesviruses. PLoS Pathog 8: e1002497.
5. Bryant NA, Davis-Poynter N, Vanderplaschen A, Alcami A (2005) Glycoprotein G interacts with glycoprotein G from several alphaherpesviruses as function broad spectrum chemokine binding proteins. EMBO J 22: 833–846.
6. Costes B, Thirion M, Dewals B, Mast J, Ackermann M, et al. (2006) Felid infectious laryngotracheitis virus gG diminishes neutrophil chemotaxis with subsequent modulation of T-cell development of novel vaccine adjuvants and warrants further investigation. J Clin Invest 105: 1613–1621.
7. Alcami A, Lira SA (2010) Modulation of chemokine activity by viruses. Curr Opin Immunol 22: 462–467.
8. Webb LM, Alcami A (2005) Virally encoded chemokine binding proteins. Mini Rev Med Chem 5: 833–840.
9. Viejo-Borbolla A, Martínez-Martín N, Nel HJ, Rueda P, Martin R, et al. (2012) Enhancement of chemokine function as an immunomodulatory strategy employed by human herpesviruses. PLoS Pathog 8: e1002497.
10. Bryant NA, Davis-Poynter N, Vanderplaschen A, Alcami A (2005) Glycoprotein G interacts with glycoprotein G from several alphaherpesviruses as function broad spectrum chemokine binding proteins. EMBO J 22: 833–846.
11. Costes B, Thirion M, Dewals B, Mast J, Ackermann M, et al. (2006) Felid infectious laryngotracheitis virus gG diminishes neutrophil chemotaxis with subsequent modulation of T-cell development of novel vaccine adjuvants and warrants further investigation. J Clin Invest 105: 1613–1621.
12. Alcami A, Lira SA (2010) Modulation of chemokine activity by viruses. Curr Opin Immunol 22: 462–467.
13. Devlin JM, Browning GF, Gilkerson JR, et al. (2010) Evaluation of immunological responses to a glycoprotein G deficient candidate vaccine strain of infectious laryngotracheitis virus. Vaccine 28: 1325–1332.
14. Fallon PG, Alcami A (2006) Pathogen-derived immunomodulatory molecules: future immunotherapies? Trends Immunol 27: 470–476.
15. Lucas A, McFadden G (2004) Secreted immunomodulatory viral proteins as novel biotherapeutics. J Immunol 173: 4765–4774.
16. Luster AD, Alon R, von Andrian UH (2005) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 6: 1102–1190.
17. Probstfeld AE (2002) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2: 106–115.
18. Wells TN, Power CA, Shaw JP, Probstfeld AE (2006) Chemokine blockers—therapeutics in the making? Trends Pharmacol Sci 27: 41–47.
19. van de Walle GR, Yu ML, Sukhumavasi W, von Einem J, Osterrieder N (2007) Herpesvirus chemokine-binding glycoprotein G (gG) efficiently inhibits neutrophil chemotaxis in vivo and in vitro. J Immunol 179: 4161–4169.
20. Alcami A, Lira SA (2010) Modulation of chemokine activity by viruses. Curr Opin Immunol 22: 462–467.
21. Devlin JM, Viejo-Borbolla A, Browning GF, Noormohammadi AH, Gilkerson JR, et al. (2010) Evaluation of immunological responses to a glycoprotein G deficient candidate vaccine strain of infectious laryngotracheitis virus. Vaccine 28: 1325–1332.
22. Banerjee S, Medina-Fatimi A, Nicholi R, Tendler D, Michetti M, et al. (2002) Safety and efficacy of low dose *Escherichia coli* enterotoxin adjuvant for urosepsis based oral immunisation against *Helicobacter pylori* in healthy volunteers. Gut 51: 634–640.
23. Sangouard S, Lee CK, Alashli M, Banerjee S, Cadoz M, et al. (2002) Safety and efficacy of *E. coli* enterotoxin adjuvant for urosepsis based rectal immunization against *Helicobacter pylori*. Vaccine 21: 194–203.
24. Aeberschier T, Bamann D, Apple HJ, Mützger W, Schneider T, et al. (2008) Correlation of T cell response and bacterial clearance in human volunteers challenged with *Helicobacter pylori* revealed by randomised controlled vaccination with Ty21a-based *Salmonella* vaccines. Gut 57: 1065–1072.
25. Engelkopershuis H, Hohmann EL (2000) Pilot study of phoP/phoQ-deleted *Salmonella enterica* serovar typhimurium expressing *Helicobacter pylori* urease in adult volunteers. Infect Immun 68: 2315–2311.
26. Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, et al. (2008) Safety and immunogenicity of an intranasal *Helicobacter pylori* vaccine in noninfected volunteers: a phase I study. Gastroenterology 135: 787–795.
27. Studdert MJ, Blackney MH (1979) Equine herpesvirus: on the differentiation of respiratory from foetal strains of type 1. Aust Vet J 55: 549–551.
28. Drummer HE, Studdert MJ, Crabbe BS (1998) Equine herpesvirus-G glycoprotein G is secreted as a disulphide-linked homodimer and is present as two homodimeric species in the virion. J Gen Virol 79 (Pt 5): 1203–1213.
29. Lee A, O’Rourke J, De Urdina MG, Robertson T, Daskalopoulos G, et al. (1997) A standardized mouse model of *Helicobacter pylori* infection: introducing the Sydney strain. Gastroenterology 112: 1386–1397.
30. Stent A, Every AL, Moloney MB, Ng GZ, Skene CD, et al. (2011) Evaluation of *Escherichia coli* heat-labile enterotoxin is safe and -infected adults. Gastroenterology 116: 804–815.
31. Stent A, Every AL, Moloney MB, Ng GZ, Skene CD, et al. (2011) Evaluation of *Escherichia coli* heat-labile enterotoxin is safe and -infected adults. Gastroenterology 116: 804–815.
32. Every AL, Ng GZ, Skene CD, Harbour SN, Walduck AK, et al. (2011) Localized suppression of inflammation at sites of *Helicobacter pylori* colonization. Infect Immun 79: 4186–4192.
33. Van de Walle GR, Kaufer BB, Chhab N, Osterrieder N (2009) Analysis of the *Helicobacter pylori* vaccine strain of infectious laryngotracheitis virus delivered via eye drop, drinking water or aerosol. Avian Pathol 37: 83–88.
34. Devlin JM, Browning GF, Hartley CA, Gilkerson JR (2007) Glycoprotein G dependent infectious laryngotracheitis virus is a candidate attenuated vaccine. Vaccine 25: 3561–3566.
35. Devlin JM, Hartley CA, Gilkerson JR, Coppo MJ, Vaz P, et al. (2011) Horizontal transmission dynamics of a glycoprotein G deficient candidate vaccine strain of infectious laryngotracheitis virus and the effect of vaccination on transmission of virulent virus. Vaccine 29: 5699–5704.
36. Alcami A, Lira SA (2010) Modulation of chemokine activity by viruses. Curr Opin Immunol 22: 462–467.
37. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R (1999) *Helicobacter pylori* virulence and genetic geography. Science 284: 1328–1333.
38. Sya S, Kohler E, Hinder I, Arnold I, Schwindener R, et al. (2009) The CD4+ T cell-mediated IFN-gamma response to *Helicobacter pylori* infection is essential for clearance and determines gastric cancer risk. J Immunol 182: 7085–7101.
39. Sutton P, Danon SJ, Walker M, Thompson LJ, Wilson J, et al. (2001) Post-immunisation gastritis and *Helicobacter pylori* infection in the mouse: a long term study. J Pathol 194: 467–473.
40. Van de Walle GR, Jarosinski KW, Osterrieder N (2008) Alphaferpevsiruses and chemokines: pas de deux not yet brought to perfection. J Virol 82: 6090–6097.
Author/s:
Baker, L; Chitas, AML; Hartley, CA; Coppo, MJC; Vaz, PK; Stent, A; Gilkerson, JR; Devlin, JM; Every, AL

Title:
Recombinant Herpesvirus Glycoprotein G Improves the Protective Immune Response to Helicobacter pylori Vaccination in a Mouse Model of Disease

Date:
2014-05-02

Citation:
Baker, L., Chitas, A. M. L., Hartley, C. A., Coppo, M. J. C., Vaz, P. K., Stent, A., Gilkerson, J. R., Devlin, J. M. & Every, A. L. (2014). Recombinant Herpesvirus Glycoprotein G Improves the Protective Immune Response to Helicobacter pylori Vaccination in a Mouse Model of Disease. PLOS ONE, 9 (5), https://doi.org/10.1371/journal.pone.0096563.

Persistent Link:
http://hdl.handle.net/11343/57327

File Description:
Published version

License:
CC BY